EUCTR2011-001646-16-IT进行中（未招募）不适用
A GSK1349572 Open Label Protocol for HIV infected, Adult Patients with Integrase Resistance
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female patients aged =18 years NOTE: all female patients of child-bearing potential should use every precaution to prevent pregnancy. Contraception guidelines include: • Complete abstinence from intercourse from 2 weeks prior to administration of DTG, throughout receipt of DTG, and for at least 2 weeks after discontinuation of DTG; • Double barrier method (male condom/spermicide, male condom/diaphragm,diaphragm/spermicide); • Approved hormonal contraception; • Any intrauterine device (IUD) with published data showing that the expected failure rate is <1% per year (not all IUDs meet this criterion); • Male partner sterilization prior to the female patient's entry into the study, and this male is the sole partner for that patient; • Any other method with published data showing that the expectedfailure rate is <1% per year. Any contraception method must be used consistently, in accordance with the approved product label and for at least 2 weeks after discontinuation of IP. All patients participating in the study should be counseled on the practice of safer sexual practices including the use of effective barrier methods (e.g., male condom/spermicide). • Documented plasma HIV-1 RNA levels =400 copies/mL within 3 months prior to the Screening visit.Documented RAL or ELV resistance in the patient's medical records (evidence of phenotypic and/or genotypic resistance must be provided to qualify for the EAP program). If resistance is not documented, Investigators may, at their own expense, test potential recruits. • Inability to construct a viable background regimen of ART with commercially available medications. • The patient/legal guardian or representative has given written informed consent to treatment prior to any program-specific assessments are initiated in accordance with country-specific regulatory authority requirements.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 990
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •Deviations from exclusion criteria are not allowed because they can potentially jeopardize patient safety. Therefore, adherence to the criteria as specified in the protocol is essential. Patients meeting any of the following criteria must not be enrolled in the program: 1. Patient has estimated creatinine clearance (CrCl) <30 mL/min via Cockcroft-Gault method [Cockcroft, 1976]. Calculated CrCl (mL/min) = (140 - age [years]) x weight (kg)/ [72 × serum creatinine (mg/100mL)] Female patients: multiply by 0.85 In order to use SI units, the following formula may be used: Calculated CrCl (mL/min) = (140 - age [years]) x weight (kg) x 1.23/serum creatinine (µmol/L) Female patients: multiply by 0.85 2. Females who are pregnant or breastfeeding. 3. Patients who have had a known or suspected allergic reaction to an INI. 4. Alanine aminotransferase (ALT) >5 times the upper limit of normal (ULN) within 1 month of treatment initiation and/or at last ALT determination. 5. ALT >3 times ULN and total bilirubin >1.5 times ULN (with >35% direct bilirubin within 1 month of treatment initiation) and/or at last ALT and bilirubin determinations. 6. Evidence for severe hepatic impairment (Child-Pugh class C). 7. Patients who are eligible for, and have access to, an actively enrolling DTG Phase III clinical trial. 8. Any condition (including but not limited to alcohol and drug use) or any active clinically significant disease or findings during Screening of medical history or physical examination, which, in the opinion of the Investigator would interfere with patient safety or compliance. 9. Patient requires or is anticipated to require any of the prohibited concomitant therapy as listed in Section 5.6.2. NOTE: Patients should not be considered for the EAP if they are eligible
- •and able to participate in any of the clinical treatment trials of DTG in
- •treatment-experienced patients (protocols ING111762, ING112961 or
- •ING112574). Please refer to any national or local requirements for
- •participation in EAPs. In that instance (assuming
- •consent is obtained), the patient should preferentially be enrolled into
- •the ongoing clinical trial to allow detailed data collection. Patients
- •should not be treated in this EAP if they have previously been treated
- •with DTG in another clinical trial.
- •Notwithstanding these minimum inclusion and exclusion criteria,
- •Investigators must also follow country specific guidelines where they
- •exist when making decisions about patients who are eligible for study
- •participation.
研究者
相似试验
进行中（未招募）
不适用
A Dolutegravir Open Label Protocol for HIV infected, Adult and Adolescents Patients with Integrase Resistance - Expanded Access ProgrammeEUCTR2011-001646-16-PLViiV Healthcare UK Limited1,000
进行中（未招募）
1 期
A Dolutegravir Open Label Protocol for HIV infected, Adult and Adolescents Patients with Integrase Resistance - Expanded Access ProgrammeTreatment of Human Immunodeficiency Virus (HIV) infection in patients with raltegravir (RAL) or elvitegravir (ELV) resistance whohave limited treatment options.MedDRA version: 14.1Level: LLTClassification code 10020194Term: HIV-2 infectionSystem Organ Class: 100000004862MedDRA version: 14.1Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862EUCTR2011-001646-16-BEViiV Healthcare UK Limited1,000
已完成
4 期
Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During PregnancyHIV InfectionNCT00246610Pfizer16
已完成
不适用
An Expanded Access Open Label Protocol of Remune (HIV-1 Immunogen) in HIV-1-Infected Adults With CD4 Count 550 Cells /Ml and Greater.HIV InfectionsNCT00002173The Immune Response Corporation
已完成
不适用
A Study of 1592U89 in HIV-Infected AdultsHIV InfectionsNCT00002200Glaxo Wellcome